ResMed Inc. (NYSE:RMD) has been given a consensus rating of “Hold” by the thirteen research firms that are currently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $65.83.

Several equities research analysts recently weighed in on RMD shares. Zacks Investment Research upgraded ResMed from a “hold” rating to a “buy” rating and set a $86.00 target price for the company in a report on Thursday, October 12th. BMO Capital Markets boosted their target price on ResMed from $70.00 to $74.00 and gave the stock a “market perform” rating in a report on Friday, October 27th. JPMorgan Chase & Co. boosted their target price on ResMed from $72.00 to $73.00 and gave the stock an “overweight” rating in a report on Monday, October 30th. Jefferies Group restated a “sell” rating and issued a $56.00 target price on shares of ResMed in a report on Thursday, October 12th. Finally, Northland Securities restated a “sell” rating and issued a $55.00 target price on shares of ResMed in a report on Friday, October 27th.

In other ResMed news, CFO Brett Sandercock sold 1,250 shares of ResMed stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $84.50, for a total value of $105,625.00. Following the transaction, the chief financial officer now directly owns 71,772 shares of the company’s stock, valued at approximately $6,064,734. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider David Pendarvis sold 6,364 shares of ResMed stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $82.20, for a total value of $523,120.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 158,929 shares of company stock worth $13,181,009. Company insiders own 1.77% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC bought a new stake in shares of ResMed during the third quarter valued at approximately $113,000. YorkBridge Wealth Partners LLC grew its position in ResMed by 4.9% in the second quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock valued at $115,000 after acquiring an additional 69 shares during the period. Toronto Dominion Bank grew its position in ResMed by 12.8% in the second quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock valued at $135,000 after acquiring an additional 197 shares during the period. BB&T Investment Services Inc. bought a new stake in ResMed in the second quarter valued at $214,000. Finally, Visionary Asset Management Inc. bought a new stake in ResMed in the third quarter valued at $214,000. Institutional investors and hedge funds own 61.81% of the company’s stock.

Shares of ResMed (RMD) traded up $0.74 during trading on Monday, hitting $87.78. The stock had a trading volume of 339,100 shares, compared to its average volume of 463,300. ResMed has a fifty-two week low of $62.64 and a fifty-two week high of $88.49. The company has a current ratio of 4.72, a quick ratio of 3.86 and a debt-to-equity ratio of 0.50. The firm has a market cap of $12,460.00, a price-to-earnings ratio of 35.54, a price-to-earnings-growth ratio of 2.22 and a beta of 0.78.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.66. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The firm had revenue of $523.66 million during the quarter, compared to analyst estimates of $506.08 million. During the same period in the previous year, the company earned $0.62 EPS. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. equities research analysts predict that ResMed will post 3.04 EPS for the current year.

TRADEMARK VIOLATION WARNING: “ResMed Inc. (RMD) Receives Consensus Rating of “Hold” from Analysts” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/15/resmed-inc-rmd-receives-consensus-rating-of-hold-from-analysts.html.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Analyst Recommendations for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.